Medical Education

EDUCALS, your online learning network

The EDUCALS network, tailored for neurology specialists and multidisciplinary teams, aims to be an essential resource for finding up-to-date nowledge on ALS.

We invite you to join us on this journey towards accuracy in ALS diagnosis and improved patient care.

REGISTER HERE

normal
left

NEW  MODULE: DIAGNOSTIC TOOLS AND MANAGEMENT STRATEGIES 
 

ALS Trial Design - icon
Module 1

ALS Trial Design
 

Learn strategies to balance endpoints’ and patients’ selection and how to better engage with pALS.

ALS Diagnosis and Referral icon
Module 2

ALS Diagnosis and Referral

Enhance diagnostic efficiency and minimise referral delays to improve patient and medical journeys.

ALS Disease Overview icon
Module 3

ALS Disease Overview 

Gain in-depth knowledge on ALS disease covering classification, epidemiology, risk factors, causes, prognosis and key pathophysiological mechanisms.

Diagnostic Tools and Management Strategies
Module 4

Diagnostic Tools and Management Strategies

Enhance your understanding of the challenges, benefits, and strategies associated with early diagnosis, including scales, biomarkers, multidisciplinary approaches, and comprehensive care.

Patient-focused initiatives

ALS Infographic to share with your patients

Check out the ALS infographic to download and share with your patients.

Clinical Trials & Publications

Image ADORE Study selected Posters
ADORE Study publications

Learn about the ADORE Study protocol design and results: an international, Phase 3, Randomized, Placebo-Controlled trial with Daily Oral Edaravone (FNP122) in people living with ALS

The publications contained in this section are subject to congress copyright permissions.

Image ADORE Study selected Posters
ADOREXT Study publications

Consult the ADOREXT study protocol design: an international, Phase 3 Open-Label Extension Study to Investigate the Long-term Safety of Daily Oral Edaravone (FNP-122) in ALS.

The publications contained in this section are subject to congress copyright permissions.

Top-line results from Phase III ADORE study in ALS. Link to Ferrer official press release (10/01/2024)